Dabigatran elimination: is haemodialysis effective?

Abstract

Dabigatran, a direct thrombin inhibitor with oral bioavailability via its pro-drug Dabigatran etexilate, has been approved in the US and Europe for both the prevention of stroke and thrombo-embolic disease in patients with non-valvular atrial fibrillation (AF), and for the prevention of venous thromboembolism after hip and knee replacement in Europe. While the traditional oral anticoagulant (OAC) warfarin reduces risk of stroke by approximately 2/3 in patients with AF (1), it is underutilised in populations in whom OAC is indicated (2), and often only achieves suboptimal anticoagulation according to time in the therapeutic range based on international normalized ratio (INR) testing (3).

Read More

Citation
Thromb Haemost 2013;109:580-1